Navigation Links
Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:4/24/2008

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 -

SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1 clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia (CIN). Findings from the fourth cohort safety review demonstrated that HspE7 was safe and well tolerated with no serious adverse events being reported.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

An evaluation by the Safety Review Committee was performed after each of the four cohorts reached five weeks of treatment (two doses plus one week of follow-up). All of the patients in the Phase 1 study were administered 500 mcg of HspE7 with each of the four cohorts receiving escalating doses of adjuvant -- 50, 500, 1,000 and 2,000 mcg. The company previously announced that HspE7 was also well tolerated in the first three cohorts.

In addition to safety data, immunological data were collected from all patients pre-treatment, following each dose of HspE7 and at the end of the study. Preliminary evaluation of biological samples collected from the study's first and second cohorts indicates that administration of HspE7 results in an E7-specific T-cell immune response. Independent research findings published by Jeffrey Weber, M.D., Ph.D., in the journal Gynecologic Oncology demonstrate that such an immune response may be associated with objective clinical responses in patients with CIN. Therefore, Nventa believes that HspE7 may successfully treat CIN by activating and enhancing the body's natural immune system. The company expects to release immunological data from the third and fourth cohorts in the coming months.

"We are pleased with the broa
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
4. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
5. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
6. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
7. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
8. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
9. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
10. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... 30, 2015 IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, August 6, 2015 ... business developments. Interested parties may access the ...
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 2011 Total quarterly revenues of ... grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel ... of $0.34 versus $0.46 for prior year ... from 2010 Company reaffirms 2011 guidance ...
... Ohio, Oct. 27, 2011 Cardinal Health today reported ... an 11 percent increase in non-GAAP diluted earnings per ... EPS from continuing operations declined 19 percent to $0.68, ... of CareFusion stock. Strong revenue growth was driven by ...
Cached Medicine Technology:Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 3Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 4Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 5Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 6Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 7Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 8Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 9Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 10Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 11Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 12Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 13Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 14Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 15Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 16Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 17Cardinal Health Reports First-Quarter Results 2Cardinal Health Reports First-Quarter Results 3Cardinal Health Reports First-Quarter Results 4Cardinal Health Reports First-Quarter Results 5Cardinal Health Reports First-Quarter Results 6Cardinal Health Reports First-Quarter Results 7Cardinal Health Reports First-Quarter Results 8Cardinal Health Reports First-Quarter Results 9Cardinal Health Reports First-Quarter Results 10Cardinal Health Reports First-Quarter Results 11Cardinal Health Reports First-Quarter Results 12Cardinal Health Reports First-Quarter Results 13Cardinal Health Reports First-Quarter Results 14Cardinal Health Reports First-Quarter Results 15Cardinal Health Reports First-Quarter Results 16Cardinal Health Reports First-Quarter Results 17Cardinal Health Reports First-Quarter Results 18
(Date:7/31/2015)... ... , ... There’s no better way to enjoy the summer weather than by ... next meal, making July the most appropriate to be National Hot Dog Month. King ... Make the next cookout different than the ones in the past. Celebrate National Hot ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries and delicious ... with custom designs, making life just a little bit sweeter for newlyweds. A ... each customer who orders one. , The bakery provides a full line of custom ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... one-day event geared to patients and family members, medical professionals, and researchers, covering ... mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied Research ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... will help treat baldness by growing new hair follicle cells//. ... hair follicles from the back of the neck, multiplying them ... BBC News. ,It initially tested the treatment on ... hair. They are to test the treatment on 20 more ...
... group of pioneering psychiatrists who worked in Saskatchewan, Canada in ... Dyck, who is working on it for the last 5 ... the University of Alberta, sited records of the psychiatrists' research, ... single dose of the hallucinogenic drug LSD, administered in a ...
... A team of scientists from the University of Adelaide, ... world breakthrough in understanding how bacterial toxins cause// severe ... Adrienne Paton from the University of Adelaide’s School of ... potent bacterial toxin kills cells by inactivating an essential ...
... Paswan promises a new policy for the poor that will ... tuberculosis, AIDS and cancer. ,"By Jan 1 we ... will offer free medication to the poor," Paswan said in ... with the help of the drug manufacturers who have agreed ...
... surgeons at The Methodist Hospital shows unprecedented improvements in ... Lucentis? for wet// age-related macular degeneration (AMD), according to ... Medicine. AMD is a major cause of central visual ... blindness in people over 60. ,Dr. David ...
... revealed that behavioral therapies can benefit children who have problems ... ,The American Academy of Sleep Medicine (AASM) appointed a ... babies and toddlers. ,According to study author Jodi ... have shown 20 to 30 percent of young children have ...
Cached Medicine News:Health News:Effective Cure for Alcoholism – A single dose of LS 2Health News:Effective Cure for Alcoholism – A single dose of LS 3Health News:Scientists Make World Breakthrough 2Health News:Free Medicines, Health Insurance for Poor Soon: Paswan 2Health News:Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements 2
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
Medicine Products: